Vergoeding 2014-2018 voor ATC-subgroep N02CC : Selectieve serotonine-agonisten
- Raming voor de totale Zvw-populatie
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| N02CC01 Sumatriptan (Imigran ®) | 14.149.700 | 13.306.500 | 12.960.000 | 11.958.200 | 11.970.700 |
| N02CC02 Naratriptan (Naramig ®) | 203.480 | 175.640 | 178.780 | 175.680 | 171.770 |
| N02CC03 Zolmitriptan (Zomig ®) | 397.240 | 284.370 | 254.980 | 249.470 | 277.550 |
| N02CC04 Rizatriptan (Maxalt ®) | 3.089.200 | 1.943.600 | 1.680.400 | 1.554.300 | 1.607.500 |
| N02CC05 Almotriptan (Almogran ®) | 600.070 | 537.310 | 447.980 | 417.750 | 390.030 |
| N02CC06 Eletriptan (Relpax ®) | 1.731.800 | 1.791.200 | 1.928.400 | 1.912.800 | 1.908.300 |
| N02CC07 Frovatriptan (Fromirex ®) | 1.549.500 | 1.524.200 | 1.032.100 | 709.300 | 704.210 |
| Totaal | 21.720.990 | 19.562.820 | 18.482.640 | 16.977.500 | 17.030.060 |